Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 3 Breast Neoplasms 3 Overweight 2 Substance Withdrawal Syndrome 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Metabolic Syndrome 1 Melanoma 1 Inflammation 1 Glioma 1 Glioblastoma 1 Dyslipidemias 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 353 Radiotherapy 177 Bevacizumab 134 Radiation 68 Magnetic Resonance Spectroscopy 63 Lomustine 43 pembrolizumab 36 Surgical Procedures, Operative 35 Irinotecan 35 Carmustine 35 Nivolumab 26 Carboplatin 25 Radiosurgery 22 Specimen Handling 21 Erlotinib Hydrochloride 20 Chemotherapy, Adjuvant 20 Radiotherapy, Intensity-Modulated 18 Aminolevulinic Acid 18 Drug Therapy 17 Cyclophosphamide 16 sargramostim 15 O(6)-benzylguanine 13 Radiotherapy, Conformal 12 Granulocyte-Macrophage Colony-Stimulating Factor 12 Everolimus 12 Blood Specimen Collection 12 Vorinostat 11 Sunitinib 11 Cilengitide 11 temsirolimus 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡